| For: | Wong R, Yuan LY. Sarcopenia and metabolic dysfunction associated steatotic liver disease: Time to address both. World J Hepatol 2024; 16(6): 871-877 [PMID: 38948439 DOI: 10.4254/wjh.v16.i6.871] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v16/i6/871.htm |
| Number | Citing Articles |
| 1 |
Yanyan Xuan, Fangfang He, Qing Liu, Dandan Dai, Dingting Wu, Yanmei Shi, Qi Yao. Elevated GGT to HDL ratio as a marker for the risk of NAFLD and liver fibrosis. Scientific Reports 2025; 15(1) doi: 10.1038/s41598-024-84649-w
|
| 2 |
Jiawen Dong, Kaitlyn M J H Dennis, Radha Venkatakrishnan, Leanne Hodson, Jeremy W Tomlinson. The Impact of Estrogen Deficiency on Liver Metabolism: Implications for Hormone Replacement Therapy. Endocrine Reviews 2025; 46(6) doi: 10.1210/endrev/bnaf018
|
| 3 |
Fan Zhang, Wenjian Li. Correlation Between Metabolic Dysfunction-Associated Steatotic Liver Disease and the Risk of Urinary Incontinence in Adult Women. International Journal of Women's Health 2024; doi: 10.2147/IJWH.S489959
|
| 4 |
思阅 李. Identification of Shared Candidate Diagnostic Biomarkers for NAFLD and Sarcopenia Based on Bioinformatics and Machine Learning. Advances in Clinical Medicine 2026; 16(04) doi: 10.12677/acm.2026.1641725
|
| 5 |
Li-Mei Liu, Cheng Qian, Kai-Rui Wan. Bidirectional regulation between the endocrine system and liver: From mechanisms to multidisciplinary clinical care. World Journal of Gastroenterology 2026; 32(6): 115232 doi: 10.3748/wjg.v32.i6.115232
|
| 6 |
Abdulrahman Ismaiel, Vera Ciornolutchii, Stefan‐Lucian Popa, Dan L. Dumitrascu. Can ammonia scavenging treat MASLD? Evaluating the evidence for L‐ornithine L‐aspartate—A systematic review. European Journal of Clinical Investigation 2026; 56(2) doi: 10.1111/eci.70185
|
| 7 |
Consensus guidelines for the diagnosis and management of metabolic dysfunction-associated steatotic liver disease in adult Asian Indians with type 2 diabetes. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2025; 19(3) doi: 10.1016/j.dsx.2025.103209
|
| 8 |
Niki G. Mourelatou, Triada Bali, Magdalini Adamantou, Lampros Chrysavgis, Christos Chologkitas, Margarita Sarri, Dimitra Pavlopoulou, Georgios Schinas, Theodoros Androutsakos, Georgia Sypsa, Dimitrios S. Karagiannakis, George Papatheodoridis, Nikolaos Tentolouris, Anastasia N. Mavrogiannaki, Evangelos Cholongitas. Evaluation of Sarcopenic Obesity in Patients with MASLD. Medical Sciences 2026; 14(2) doi: 10.3390/medsci14020257
|
| 9 |
M. Yu. Nadinskaia, S. V. Okovityi, V. A. Prikhodko, A. F. Sheptulina, T. A. Deeva, M. V. Maevskaya, M. F. Osipenko. Clinical significance of hyperammonemia in non-alcoholic fatty liver disease. Meditsinskiy sovet = Medical Council 2026; (8) doi: 10.21518/ms2026-204
|
| 10 |
Shuangshuang Hou, Yang Yu, Nanbo Li, Wenjing Yu, Zhiyuan Dai, He Li, Lianyi Guo, Jiajun Yin, Ju Wu. Preoperative albumin-bilirubin grade combined with sarcopenia predicts long-term outcomes after laparoscopic gastrectomy for advanced gastric cancer. BMC Gastroenterology 2025; 25(1) doi: 10.1186/s12876-025-04173-7
|
| 11 |
Noha M. Gamil, Habiba A. Elsayed, Esraa T. Salah, Heba A. Mostafa, Riham A. El-Shiekh, Heba R. Ghaiad, Hebatollah E. Eitah. Decoding the mechanistic basis of liver–muscle communication in health and disease. Naunyn-Schmiedeberg's Archives of Pharmacology 2026; 399(8) doi: 10.1007/s00210-026-05015-3
|
| 12 |
Sizhe Wan, Mingkai Li, Wanjun Li, Yuexiang Ren, Yuankai Wu, Qingtian Luo, Wei Gong. Development and validation of a multimodal model integrating gut microbiota and metabolite for identifying sarcopenia in patients with MASLD: a study from two centers in China. Nutrition Journal 2025; 24(1) doi: 10.1186/s12937-025-01198-2
|
| 13 |
Kiook Baek, Jung Gil Park, Yu Rim Lee, Soo Young Park, Young Oh Kweon, Won Young Tak. Muscle Mass as a Causal Factor in MASLD: Insights from a Genome-Wide Association Study and Bidirectional Mendelian Randomization Using Data from the Korean Genome and Epidemiology Study. Gut and Liver 2026; 20(4) doi: 10.5009/gnl250100
|
| 14 |
Carlos Jiménez-Cortegana, Soledad López-Enríquez, Gonzalo Alba, Consuelo Santa-María, Gracia M. Martín-Núñez, Francisco J. Moreno-Ruiz, Sergio Valdés, Sara García-Serrano, Cristina Rodríguez-Díaz, Ailec Ho-Plágaro, María I. Fontalba-Romero, Eduardo García-Fuentes, Lourdes Garrido-Sánchez, Víctor Sánchez-Margalet. The Expression of Genes Related to Reverse Cholesterol Transport and Leptin Receptor Pathways in Peripheral Blood Mononuclear Cells Are Decreased in Morbid Obesity and Related to Liver Function. International Journal of Molecular Sciences 2024; 25(14) doi: 10.3390/ijms25147549
|
| 15 |
Yan Li, Wei Feng, Xiaojie Sun, Yujie Dong. Causal and mediating link between sarcopenia and nonalcoholic fatty liver disease: A bidirectional two-sample, two-step Mendelian randomization study. Nutrition, Metabolism and Cardiovascular Diseases 2025; 35(12) doi: 10.1016/j.numecd.2025.104207
|
| 16 |
Yea-Chan Lee, Hye Sun Lee, Soyoung Jeon, Yae-Ji Lee, Yu-Jin Kwon, Ji-Won Lee. Assessing Nutritional Factors for Metabolic Dysfunction-Associated Steatotic Liver Disease via Diverse Statistical Tools. Diabetes & Metabolism Journal 2026; 50(1) doi: 10.4093/dmj.2025.0026
|
| 17 |
Shinya Sato, Hiroaki Takaya, Tadashi Namisaki, Tatsuya Nakatani, Jun-ichi Hanatani, Yuki Tsuji, Koh Kitagawa, Norihisa Nishimura, Kosuke Kaji, Hitoshi Yoshiji. Diabetes as a Risk Factor for Sarcopenia in Patients with MASH-Related Cirrhosis. Journal of Clinical Medicine 2025; 14(24) doi: 10.3390/jcm14248691
|
| 18 |
Aalam Sohal, Carol Singh, Ragini Sharma, Mehul Solanki, Mohammad Naseem, Sampada. Pathophysiology of depression and anxiety in metabolic dysfunction-associated steatotic liver disease. World Journal of Gastrointestinal Pathophysiology 2025; 16(4): 111029 doi: 10.4291/wjgp.v16.i4.111029
|
| 19 |
Yusuf Yilmaz, Alina M. Allen, Jérôme Boursier, Juan P. Arab. Association of Metabolic Dysfunction-Associated Steatotic Liver Disease with Extrahepatic Cancers and Sarcopenia. Clinics in Liver Disease 2026; 30(2) doi: 10.1016/j.cld.2025.12.002
|
| 20 |
Fan Zhang, Longgen Liu, Wenjian Li. Correlation of sarcopenia with progression of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease: a study from two cohorts in China and the United States. Nutrition Journal 2025; 24(1) doi: 10.1186/s12937-025-01081-0
|
| 21 |
Marwan S Al-Nimer. Sarcopenia and metabolic dysfunction-associated steatotic liver disease: The role of exercise-related biomarkers. World Journal of Hepatology 2025; 17(2): 101165 doi: 10.4254/wjh.v17.i2.101165
|
| 22 |
Hiroyuki Ito, Chizuko Yukawa, Toshiko Mori, Chiaki I, Mizuki Matsushita, Suzuko Matsumoto, Hideyuki Inoue, Shinichi Antoku, Tomoko Yamasaki, Kenichi Nishio, Sayuri Miura. Fibrosis-4 (FIB-4) Index Is Associated With Skeletal Muscle Mass in Japanese Patients With Type 2 Diabetes: A Single-Center Retrospective Cross-Sectional Study. Cureus 2026; doi: 10.7759/cureus.107785
|
| 23 |
Anoushka Shenoy, Aijaz Ahmed, Donghee Kim. Extrahepatic manifestation of metabolic dysfunction-associated steatotic liver disease. Metabolism and Target Organ Damage 2025; 5(3) doi: 10.20517/mtod.2025.73
|
| 24 |
Chia-Chih Kuo, Chi-Hsing Chen, Hsing-Tao Kuo, Chih-Cheng Lai. Clinical outcomes of lean metabolic dysfunction-associated steatotic liver disease by phenotypic subtypes. Journal of Gastroenterology 2026; doi: 10.1007/s00535-026-02481-7
|
| 25 |
Clelia Asero, Cecilia Oliveri, Maria Stella Franzè, Giorgio Basile, Antonino Catalano, Irene Cacciola. Body composition assessment for risk stratification of hepatic steatosis in patients with type 2 diabetes and MASLD undergoing osteoporosis screening. Frontiers in Endocrinology 2026; 17 doi: 10.3389/fendo.2026.1901793
|